Incyte Corp is based out of Wilmington. Incyte is a biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation. Co.'s pipeline includes compounds in several stages, ranging from preclinical to commercialized product. Co.'s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used as a treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Co. has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company.Whalewisdom has at least 3 13D filings, 10 13G filings, and 454 Form 4 filings The firm has no submitted 13F filings and does not appear to be an investment advisor.
Contact Info
Contact information is taken directly from publicly disclosed SEC filings.
INCYTE CORP1801 AUGUSTINE CUT-OFF
WILMINGTON DE 19803
Business Phone: 3024986700
SEC SIC CODE:
8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Current 13D/G Holdings
Stock | Sector | Shares Held | Market Value | Rank | Source | Source Date |
---|---|---|---|---|---|---|
Merus BV | HEALTH CARE | 4,004,554 | 183,929,165 | 1 | 13G | 2024-03-25 |